Arama Sonuçları - Xue‐Ning Yang

Sonuçları Daraltın
  1. 1
    Complete mediastinal lymphadenectomy: the core component of the multidisciplinary therapy in resectable non-small cell lung cancer

    Complete mediastinal lymphadenectomy: the core component of the multidisciplinary therapy in resectable non-small cell lung cancer Yazar: Wen‐Zhao Zhong, Xue‐Ning Yang, Jianling Bai, Jin‐Ji Yang, Christian Manegold, Yi‐Long Wu

    Baskı/Yayın Bilgisi 2008
    Tam Metin Erişim Tam Metin Erişim
    Revisão
    Favorilerime ekle
    Kaydedildi:
  2. 2
    Trends in the incidence, treatment, and survival of patients with lung cancer in the last four decades

    Trends in the incidence, treatment, and survival of patients with lung cancer in the last four decades Yazar: Lu T, Xue‐Ning Yang, Yongsheng Huang, Meng Zhao, Min Li, Ke Ma, Yin Jiang-tao, Cheng Zhan, Qi Wang

    Baskı/Yayın Bilgisi 2019
    Artigo
    Favorilerime ekle
    Kaydedildi:
  3. 3
    Neoadjuvant Crizotinib in Resectable Locally Advanced Non–Small Cell Lung Cancer with ALK Rearrangement

    Neoadjuvant Crizotinib in Resectable Locally Advanced Non–Small Cell Lung Cancer with ALK Rearrangement Yazar: Chao Zhang, Shaolei Li, Qiang Nie, Song Dong, Yang Shao, Xue‐Ning Yang, Yi‐Long Wu, Yue Yang, Wen‐Zhao Zhong

    Baskı/Yayın Bilgisi 2018
    Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  4. 4
    Multiomics analysis reveals a distinct response mechanism in multiple primary lung adenocarcinoma after neoadjuvant immunotherapy

    Multiomics analysis reveals a distinct response mechanism in multiple primary lung adenocarcinoma after neoadjuvant immunotherapy Yazar: Chao Zhang, Kai Yin, Siyang Liu, Li–Xu Yan, Jian Su, Yi‐Long Wu, Xu‐Chao Zhang, Wen‐Zhao Zhong, Xue-Ning Yang

    Baskı/Yayın Bilgisi 2021
    Tam Metin Erişim Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  5. 5
    BCL11A overexpression predicts survival and relapse in non-small cell lung cancer and is modulated by microRNA-30a and gene amplification

    BCL11A overexpression predicts survival and relapse in non-small cell lung cancer and is modulated by microRNA-30a and gene amplification Yazar: Ben‐Yuan Jiang, Xuchao Zhang, Jian Su, Wei Meng, Xue‐Ning Yang, Jin‐Ji Yang, Qing Zhou, Zhiyong Chen, Zhihong Chen, Zhi Xie, Shiliang Chen, Yi‐Long Wu

    Baskı/Yayın Bilgisi 2013
    Tam Metin Erişim Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  6. 6
    Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression

    Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression Yazar: Xu‐Chao Zhang, Shirley Zhang, Xue‐Ning Yang, Jin‐Ji Yang, Qing Zhou, Lucy Yin, Shejuan An, Jia-Yin Lin, Shiliang Chen, Zhi Xie, Mike Zhu, Xiaolin Zhang, Yi‐Long Wu

    Baskı/Yayın Bilgisi 2010
    Tam Metin Erişim Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  7. 7
    Serial cfDNA assessment of response and resistance to EGFR-TKI for patients with EGFR-L858R mutant lung cancer from a prospective clinical trial

    Serial cfDNA assessment of response and resistance to EGFR-TKI for patients with EGFR-L858R mutant lung cancer from a prospective clinical trial Yazar: Qing Zhou, Jin‐Ji Yang, Zhihong Chen, Xu‐Chao Zhang, Hong‐Hong Yan, Chong‐Rui Xu, Jian Su, Hua‐Jun Chen, Hai‐Yan Tu, Wen‐Zhao Zhong, Xue‐Ning Yang, Yi‐Long Wu

    Baskı/Yayın Bilgisi 2016
    Tam Metin Erişim Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  8. 8
    Predictive value of TCR Vβ-Jβ profile for adjuvant gefitinib in EGFR mutant NSCLC from ADJUVANT-CTONG 1104 trial

    Predictive value of TCR Vβ-Jβ profile for adjuvant gefitinib in EGFR mutant NSCLC from ADJUVANT-CTONG 1104 trial Yazar: Cunte Chen, Si‐Yang Maggie Liu, Yedan Chen, Qiuxiang Ou, Hua Bao, Ling Xu, Yikai Zhang, Wenzhao Zhong, Qing Zhou, Xue‐Ning Yang, Yang Shao, Yi‐Long Wu, Si‐Yang Liu, Yangqiu Li

    Baskı/Yayın Bilgisi 2022
    Tam Metin Erişim Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  9. 9
    Phase II study of biomarker-guided neoadjuvant treatment strategy for IIIA-N2 non-small cell lung cancer based on epidermal growth factor receptor mutation status

    Phase II study of biomarker-guided neoadjuvant treatment strategy for IIIA-N2 non-small cell lung cancer based on epidermal growth factor receptor mutation status Yazar: Wen‐Zhao Zhong, Xue‐Ning Yang, Hong‐Hong Yan, Xu‐Chao Zhang, Jian Su, Zhihong Chen, Ri-Qiang Liao, Qiang Nie, Song Dong, Qing Zhou, Jin‐Ji Yang, Hai‐Yan Tu, Yi‐Long Wu

    Baskı/Yayın Bilgisi 2015
    Tam Metin Erişim Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  10. 10
    Identification of Enriched Driver Gene Alterations in Subgroups of Non-Small Cell Lung Cancer Patients Based on Histology and Smoking Status

    Identification of Enriched Driver Gene Alterations in Subgroups of Non-Small Cell Lung Cancer Patients Based on Histology and Smoking Status Yazar: She-Juan An, Zhi Hong Chen, Jian Su, Xu‐Chao Zhang, Wen-Zhao Zhong, Jin-Ji Yang, Qing Zhou, Xue-Ning Yang, Ling Huang, Ji-Lin Guan, Qiang Nie, Hong-Hong Yan, Tony Mok, Yi‐Long Wu

    Baskı/Yayın Bilgisi 2012
    Tam Metin Erişim Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  11. 11
    <i>EGFR</i> Mutation Heterogeneity and the Mixed Response to EGFR Tyrosine Kinase Inhibitors of Lung Adenocarcinomas

    <i>EGFR</i> Mutation Heterogeneity and the Mixed Response to EGFR Tyrosine Kinase Inhibitors of Lung Adenocarcinomas Yazar: Zhiyong Chen, Wen‐Zhao Zhong, Xu‐Chao Zhang, Jian Su, Xue-Ning Yang, Zhi Hong Chen, Jin-Ji Yang, Qing Zhou, Hong-Hong Yan, She-Juan An, Hua-Jun Chen, Ben‐Yuan Jiang, Tony Mok, Yi‐Long Wu

    Baskı/Yayın Bilgisi 2012
    Tam Metin Erişim Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  12. 12
    Establishment of patient-derived non-small cell lung cancer xenograft models with genetic aberrations within EGFR, KRAS and FGFR1: useful tools for preclinical studies of targeted therapies

    Establishment of patient-derived non-small cell lung cancer xenograft models with genetic aberrations within EGFR, KRAS and FGFR1: useful tools for preclinical studies of targeted... Yazar: Xu‐Chao Zhang, Jingchuan Zhang, Ming Li, Xiao-sui Huang, Xue‐Ning Yang, Wen‐Zhao Zhong, Liang Xie, Lin Zhang, Minhua Zhou, Paul R. Gavine, Xinying Su, Zheng Li, Guanshan Zhu, Ping Zhan, Qunsheng Ji, Yi‐Long Wu

    Baskı/Yayın Bilgisi 2013
    Tam Metin Erişim Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  13. 13
    A phase III randomised controlled trial of erlotinib vs gefitinib in advanced non-small cell lung cancer with EGFR mutations

    A phase III randomised controlled trial of erlotinib vs gefitinib in advanced non-small cell lung cancer with EGFR mutations Yazar: Jin‐Ji Yang, Qing Zhou, Hong‐Hong Yan, X C Zhang, H J Chen, Hai‐Yan Tu, Z Wang, Chong‐Rui Xu, Jian Su, Banglu Wang, Bo Jiang, Xiaoyan Bai, Wen‐Zhao Zhong, Xue‐Ning Yang, Yi‐Long Wu

    Baskı/Yayın Bilgisi 2017
    Tam Metin Erişim Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  14. 14
    Genomic Landscape and Immune Microenvironment Features of Preinvasive and Early Invasive Lung Adenocarcinoma

    Genomic Landscape and Immune Microenvironment Features of Preinvasive and Early Invasive Lung Adenocarcinoma Yazar: Chao Zhang, Jianjun Zhang, Fang-Ping Xu, Yin-Guang Wang, Zhi Xie, Jian Su, Song Dong, Qiang Nie, Yang Shao, Qing Zhou, Jin-Ji Yang, Xue-Ning Yang, Xu‐Chao Zhang, Zhi Li, Yi‐Long Wu, Wen‐Zhao Zhong

    Baskı/Yayın Bilgisi 2019
    Tam Metin Erişim Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  15. 15
    Genetic and Immune Profiles of Solid Predominant Lung Adenocarcinoma Reveal Potential Immunotherapeutic Strategies

    Genetic and Immune Profiles of Solid Predominant Lung Adenocarcinoma Reveal Potential Immunotherapeutic Strategies Yazar: Zhong‐Yi Dong, Chao Zhang, Yufa Li, Jian Su, Zhi Xie, Si‐Yang Maggie Liu, Li–Xu Yan, Zhihong Chen, Xue‐Ning Yang, Jun‐Tao Lin, Hai‐Yan Tu, Jin‐Ji Yang, Qing Zhou, Yue‐Li Sun, Wen‐Zhao Zhong, Yi‐Long Wu

    Baskı/Yayın Bilgisi 2017
    Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  16. 16
    Neoadjuvant SHR-1701 with or without chemotherapy in unresectable stage III non-small-cell lung cancer: A proof-of-concept, phase 2 trial

    Neoadjuvant SHR-1701 with or without chemotherapy in unresectable stage III non-small-cell lung cancer: A proof-of-concept, phase 2 trial Yazar: Qing Zhou, Yi Pan, Xue‐Ning Yang, Yanqiu Zhao, Guang Han, Qingsong Pang, Zhenfa Zhang, Qifeng Wang, Jun Yao, Hui Wang, Weihua Yang, Baogang Liu, Qixun Chen, Xianghui Du, Kaican Cai, Baosheng Li, Yunchao Huang, Xiao Li, Song Li, Wei Shi, Yi‐Long Wu

    Baskı/Yayın Bilgisi 2024
    Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  17. 17
    Clinical modes of EGFR tyrosine kinase inhibitor failure and subsequent management in advanced non-small cell lung cancer

    Clinical modes of EGFR tyrosine kinase inhibitor failure and subsequent management in advanced non-small cell lung cancer Yazar: Jin‐Ji Yang, Hua‐Jun Chen, Hong‐Hong Yan, Xu‐Chao Zhang, Qing Zhou, Jian Su, Zhen Wang, Chong‐Rui Xu, Yi-Sheng Huang, Bin-Chao Wang, Xue‐Ning Yang, Wen‐Zhao Zhong, Qiang Nie, Ri-Qiang Liao, Ben‐Yuan Jiang, Song Dong, Yi‐Long Wu

    Baskı/Yayın Bilgisi 2012
    Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  18. 18
    EGFR L792H and G796R: Two Novel Mutations Mediating Resistance to the Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib

    EGFR L792H and G796R: Two Novel Mutations Mediating Resistance to the Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib Yazar: Qi Zhang, Xu‐Chao Zhang, Jin‐Ji Yang, Zhenfan Yang, Yu Bai, Jian Su, Zheng Wang, Zhou Zhang, Yang Shao, Qing Zhou, Jin‐Hyoung Kang, E‐E Ke, Yichen Zhang, Zhong‐Yi Dong, Zhihong Chen, Hai‐Yan Tu, Wen‐Zhao Zhong, Xue‐Ning Yang, Yi‐Long Wu

    Baskı/Yayın Bilgisi 2018
    Tam Metin Erişim Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  19. 19
    Lung Cancers with Concomitant <i>EGFR</i> Mutations and <i>ALK</i> Rearrangements: Diverse Responses to EGFR-TKI and Crizotinib in Relation to Diverse Receptors Phosphorylation

    Lung Cancers with Concomitant <i>EGFR</i> Mutations and <i>ALK</i> Rearrangements: Diverse Responses to EGFR-TKI and Crizotinib in Relation to Diverse Receptors Phosphorylation Yazar: Jin-Ji Yang, Xu‐Chao Zhang, Jian Su, Chong‐Rui Xu, Qing Zhou, Hong-Xia Tian, Zhi Xie, Hua-Jun Chen, Yi-Sheng Huang, Ben‐Yuan Jiang, Zhen Wang, Bin-Chao Wang, Xue-Ning Yang, Wen‐Zhao Zhong, Qiang Nie, Ri-Qiang Liao, Tony Mok, Yi‐Long Wu

    Baskı/Yayın Bilgisi 2014
    Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  20. 20
    Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 <i>EGFR</i>-Mutant Non–Small-Cell Lung Cancer (EMERGING-CTONG 1103): A Randomized Phase II Study

    Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 <i>EGFR</i>-Mutant Non–Small-Cell Lung Cancer (EMERGING-CTONG 1103): A Randomized Phase II Stu... Yazar: Wen‐Zhao Zhong, Ke‐Neng Chen, Chun Chen, Chundong Gu, Jun Wang, Xue‐Ning Yang, Weimin Mao, Qun Wang, Guibin Qiao, Ying Cheng, Lin Xu, Changli Wang, Mingwei Chen, Xiaozheng Kang, Wanpu Yan, Hong‐Hong Yan, Ri-Qiang Liao, Jin‐Ji Yang, Xu‐Chao Zhang, Qing Zhou, Yi‐Long Wu

    Baskı/Yayın Bilgisi 2019
    Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:

Arama Araçları: